HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib Sensitive: B - Late Trials pyrotinib Sensitive : B	pyrotinib Sensitive: B - Late Trials pyrotinib Sensitive : B
HER-2 exon 20 mutation	Non Small Cell Lung Cancer	HER-2 exon 20 mutation	Non Small Cell Lung Cancer	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: B - Late Trials trastuzumab + pyrotinib Sensitive : B	trastuzumab + pyrotinib Sensitive: B - Late Trials trastuzumab + pyrotinib Sensitive : B
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + neratinib Sensitive: B - Late Trials trastuzumab + neratinib Sensitive : B	trastuzumab + neratinib Sensitive: B - Late Trials trastuzumab + neratinib Sensitive : B
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	neratinib Sensitive: B - Late Trials neratinib Sensitive : B	neratinib Sensitive: B - Late Trials neratinib Sensitive : B

HER4 inhibitor

HER4 inhibitor

Associations(204)

Associations
(204)